Clinical Impact of Carotid Plaque Score rather than Carotid Intima–Media Thickness on Recurrence of Atherosclerotic Cardiovascular Disease Events

Hayato Tada, Tamami Nakagawa, Hirofumi Okada, Takuya Nakahashi, Mika Mori, Kenji Sakata, Atsushi Nohara, Masayuki Takamura and Masa-aki Kawashiri

Department of Cardiology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan

**Aim:** Carotid plaque score (cPS) reflecting throughout the carotid artery plaque burden may be a better marker than carotid intima–media thickness (cIMT) is. We aimed to compare the prognostic utility of these measurements in patients with atherosclerotic cardiovascular disease (ASCVD).

**Methods:** We retrospectively examined 2,035 Japanese patients with ASCVD who underwent carotid ultrasonography between January 2008 and December 2015 at Kanazawa University Hospital. Median follow-up period was 4 years. We used Cox models that adjusted for established risk factors of ASCVD, including age, gender, hypertension, diabetes, smoking, and serum lipids to assess the association of cIMT as well as cPS with major adverse cardiac events (MACE). MACE was defined as all-cause mortality or rehospitalization for a cardiovascular-related illness.

**Results:** During follow-up, 243 participants experienced MACE. After adjustment for established risk factors, cPS was associated with MACE (hazard ratio [HR] = 3.38 for top quintile vs. bottom quintile of cPS; 95% confidence interval [CI] 1.82–6.27; \( P \) trend < 0.001), while cIMT was not (HR=0.88, \( P \)=0.57). Addition of the cPS to established risk factors significantly improved risk discrimination (C-index 0.726 vs. 0.746; \( P \)=0.017).

**Conclusion:** These results suggest that cPS, rather than cIMT may be a better marker to identify increased risk for recurrence of MACE among patients with secondary prevention setting.

**Key words:** Atherosclerotic cardiovascular disease, Carotid ultrasonography, Risk stratification, Secondary prevention

**Introduction**

Although the prognosis after suffering from atherosclerotic cardiovascular disease (ASCVD) has been improved with the introduction of primary coronary angioplasty as well as medical treatment such as LDL-lowering therapies and anti-platelet therapies\(^1\)\(^-\)\(^3\), secondary prevention of these patients is still one of the major challenges for cardiologists. Identifying individuals at the higher risk for recurrent cardiovascular events and, then, aggressively addressing modifiable risk factors in these individuals may be beneficial regarding health outcomes and cost.

Carotid intima–media thickness (cIMT) determined by less-invasive ultrasonography has been shown to be a surrogate marker for coronary atherosclerosis\(^4\), and increased cIMT has been shown to be associated with future cardiovascular events\(^5\)\(^-\)\(^7\). On the other hand, carotid plaque score (cPS) reflecting throughout the carotid artery plaque burden may be better marker. Our previous study has shown that the carotid plaque score (cPS), reflecting the cumulative atherosclerotic burden of the carotid artery, is a more useful parameter to predict the atherosclerotic severity of the coronary artery than cIMT in patients with familial hypercholesterolemia (FH)\(^8\). Some previous

---

Copyright © 2019 Japan Atherosclerosis Society. This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
studies have shown that cPS or carotid plaque burden was better marker for severity of coronary artery disease or the first cardiovascular events among primary prevention group. However, few data exist regarding the clinical impact of cPS on the recurrence of ASCVD, comparing that of cIMT in a setting of secondary prevention. Accordingly, we aimed to compare the prognostic utility of these measurements among patients with ASCVD. Moreover, such modality could help us to estimate when and how rapidly coronary atherosclerosis in patients with ASCVD develop. Accordingly, we aimed (1) to compare the prognostic utility of these measurements and (2) to estimate the onset and progression of carotid atherosclerosis in patients of a secondary prevention setting.

Materials and Methods

Study Subjects

In total, 2,132 consecutive patients who had any histories of ASCVD events and underwent carotid ultrasonography between January 2006 and December 2015 were retrospectively analyzed. Among the 2,132 patients, 97 patients lacking data (5%) were excluded (Supplemental Fig. 1). Thus, 2,035 patients with ASCVD whose ages ranged from 14 to 95 years were included in the analysis (male=1,253, mean age=65 ±12 years, mean LDL cholesterol=115±36 mg/dL).

Clinical Evaluations

Blood samples were drawn for assays after overnight fasting. Serum levels of total and HDL cholesterol and triglycerides were enzymatically determined (Qualigent, Sekisui Medical, Tokyo, Japan) using automated instrumentation based on previously described assays. Hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or treatment with antihypertensive medications. The presence of diabetes was defined as described previously by the Japan Diabetes Society. Smoking status was defined as current smoking habits. Left ventricular ejection fraction (LVEF) was calculated either by modified Simpson’s method or by Teichholz method. We defined major adverse cardiac events (MACE) as either all-cause death, including cardiac death, ST elevated myocardial infarction (STEMI), non-ST elevated myocardial infarction (NSTEMI), unstable angina pectoris (UAP), staged percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), ischemic as well as hemorrhagic stroke, heart failure requiring hospital admission.

Carotid Ultrasonography

The parameters for carotid ultrasonography were measured using the Apio carotid ultrasonography machine (Toshiba Medical Systems, Tokyo, Japan) with a 7.5-MHz transducer by trained sonographers who were blinded to the clinical data. cIMT was recorded during ultrasonography as described previously. In brief, cIMT from the right and left sides was measured from the far wall, the location of which was identified as the vertical distance from the leading edge of the first to the second echogenic line. Three cIMT determinations were measured in the walls at the site of the greatest thickness for each common carotid artery, and these measurements of both the arteries were averaged and expressed as the mean cIMT. In addition, cPS was computed by summing the maximal thickness of plaques, that were defined as focal intima–media thickening ≥1.1 mm, in each segment on both sides (a+b+c+ thickness of the contra-lateral plaques in each segment on both sides) as described previously.

Ethical Consideration

The Ethics Committee of Kanazawa University approved this study. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, revised in 2008. Informed consent was obtained from all the subjects for inclusion in the study.

Statistical Analysis

Continuous variables are presented as mean±standard deviation, and categorical variables are expressed as counts and percentages. For values lacking a normal distribution, the median and interquartile range are reported. Mean values of continuous variables were compared using Student’s t-test for independent data, and median values were compared using the nonparametric Mann Whitney U-test/Wilcoxon rank-sum test. Categorical variables were compared using the chi-square test. Hazard ratios were determined adjusted for age, sex, hypertension, current smoking, triglyceride, LDL cholesterol, HDL cholesterol, anti-platelet therapy, and lipid-lowering therapy. Hazard ratios for occurrence of endpoint events were determined for each quintile of cPS, with quintile 1 serving as the referent group. The cumulative fraction of events was estimated as 1 minus the Kaplan-Meier estimate of survival free of event. The differences of the cumulative fraction of events between subgroups were assessed by the log-rank test. Receiver-operating characteristic analysis was per-
Factors Associated with MACE

Next, we investigated the factors associated with MACE, including carotid ultrasonographic parameters (Table 3). cPS was significantly associated with MACE (HR = 1.08, 95% CI, 1.04–1.12, p < 0.001) after adjustment for established risk factors including age, gender, hypertension, diabetes, smoking, triglyceride, LDL cholesterol, HDL cholesterol, and LVEF, while cIMT was not associated with MACE (HR = 0.89, 95% CI, 0.52–1.49, p = 0.61).

Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>All (n = 2,035)</th>
<th>MACE Yes (n = 243)</th>
<th>MACE No (n = 1,792)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65 ± 12</td>
<td>69 ± 9</td>
<td>65 ± 13</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Men</td>
<td>1,253 (62 %)</td>
<td>1,066 (59 %)</td>
<td>1,239 (69 %)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1,459 (72 %)</td>
<td>1,383 (72 %)</td>
<td>1,535 (84 %)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1,531 (41 %)</td>
<td>1,383 (41 %)</td>
<td>1,648 (47 %)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking</td>
<td>1,122 (55 %)</td>
<td>1,066 (52 %)</td>
<td>1,176 (65 %)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>192 ± 42</td>
<td>180 ± 40</td>
<td>194 ± 42</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Low-density lipoprotein choles-</td>
<td>115 ± 36</td>
<td>108 ± 34</td>
<td>116 ± 37</td>
<td>0.004</td>
</tr>
<tr>
<td>terol (mg/dL)</td>
<td>115 ± 36</td>
<td>108 ± 34</td>
<td>116 ± 37</td>
<td>0.004</td>
</tr>
<tr>
<td>High-density lipoprotein choles-</td>
<td>52 ± 16</td>
<td>46 ± 13</td>
<td>53 ± 16</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>terol (mg/dL)</td>
<td>52 ± 16</td>
<td>46 ± 13</td>
<td>53 ± 16</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td>106 [75–154]</td>
<td>108 [75–156]</td>
<td>106 [73–154]</td>
<td>0.79</td>
</tr>
<tr>
<td>Anti-platelet therapy</td>
<td>1,983 (97 %)</td>
<td>241 (99 %)</td>
<td>1,742 (97 %)</td>
<td>0.142</td>
</tr>
<tr>
<td>Lipid-lowering therapy</td>
<td>1,846 (91 %)</td>
<td>236 (97 %)</td>
<td>1,610 (90 %)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Carotid IMT (mm)</td>
<td>0.8 [0.7–1.0]</td>
<td>0.8 [0.7–1.0]</td>
<td>0.8 [0.7–1.0]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Carotid plaque score</td>
<td>7.4 [3.4–12.3]</td>
<td>12.2 [8.0–16.5]</td>
<td>6.8 [3.1–11.4]</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

MACE: major adverse cardiac events, IMT: intima-media thickness

Table 2. Type of MACE

<table>
<thead>
<tr>
<th>Type of MACE</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause death</td>
<td>89 (36 %)</td>
</tr>
<tr>
<td>death associated with ASCVD</td>
<td>53 (22 %)</td>
</tr>
<tr>
<td>death not-associated with ASCVD</td>
<td>36 (15 %)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>89 (37 %)</td>
</tr>
<tr>
<td>STEMI</td>
<td>7 (3 %)</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>17 (7 %)</td>
</tr>
<tr>
<td>UAP</td>
<td>18 (7 %)</td>
</tr>
<tr>
<td>staged PCI/CABG</td>
<td>47 (19 %)</td>
</tr>
<tr>
<td>Stroke</td>
<td>19 (8 %)</td>
</tr>
<tr>
<td>ischemic stroke</td>
<td>14 (6 %)</td>
</tr>
<tr>
<td>hemorrhagic stroke</td>
<td>5 (2 %)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>46 (19 %)</td>
</tr>
</tbody>
</table>


Reproducibility of Measurements

Supplemental Fig. 2 and Supplemental Fig. 3 show intra- and interobserver reproducibility for measurements of cIMT and cPS. Bland-Altman analysis demonstrated good agreements between both within intraobserver with a CV of 9.1%, 10.4% and within interobserver with a CV of 9.9%, 11.1% for measurements cIMT, and cPS, respectively.

Baseline Characteristics

Table 1 illustrates the baseline characteristics of the study population. We observed 243 MACE events during the median 4 years of follow-up period. Table 2 illustrates details of MACE. As expected, the patients with MACE were significantly older than those without ASCVD. Frequencies of other traditional risk factors such as male gender, hypertension, diabetes, and smoking habits were significantly higher and that of HDL cholesterol was significantly lower in patients with MACE than in those without. Under these conditions, cIMT and cPS were significantly higher in patients with MACE than in those without.
The Power of cPS for Predicting MACE

When the patients were divided into 5 groups based on cPS quintiles, those with the highest cPS had 3.38 fold greater risk of MACE than those with lowest quintile (95%CI 1.82–6.27, \(p\) < 0.001 vs. lowest cPS, Table 4). Moreover, cumulative MACE rate increased according to quintile of the cPS (Log-rank trend, \(p\) < 0.001, Fig. 2).

Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: March 25, 2019    Published online: May 18, 2019
Carotid Plaque Burden and Recurrence ASCVD

5

= 0.01748) after the addition of cPS information to the model. To assess the discriminatory potential of these parameters, we also assessed the continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI). We found that the addition of cIMT or cPS to the traditional risk factor model improved reclassification (continuous NRI = 0.227, 95% CI = 0.106–0.358, \( p \) < 0.001; IDI =

Risk Discrimination by cPS

We investigated whether the discrimination of a model based on the established traditional risk factors, including age, gender, hypertension, diabetes, smoking, triglyceride, LDL cholesterol, and HDL cholesterol differed from that of a model that also included cPS. The C-statistic for the traditional risk factors model was 0.726, which increased to 0.746 (Fig. 3, \( p \) = 0.01748) after the addition of cPS information to the model. To assess the discriminatory potential of these parameters, we also assessed the continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI). We found that the addition of cIMT or cPS to the traditional risk factor model improved reclassification (continuous NRI = 0.227, 95% CI = 0.106–0.358, \( p \) < 0.001; IDI =

Fig. 2. Cumulative event rate divided by carotid plaque score quintile
X-axis represents follow-up period (year). Y-axis represents event rate.

Fig. 3. Receiver-operating characteristic curve
The black line (model 1) indicates the receiver-operating characteristic curve using traditional risk factors, including age, gender, hypertension, diabetes, smoking, triglyceride, LDL cholesterol, HDL cholesterol. The red line (model 2) indicates the receiver-operating characteristic curve using traditional risk factors and carotid plaque score.
On average, carotid atherosclerosis may start to develop at 27 and 32 years of age in male and female patients in a secondary prevention setting, respectively. Despite the significantly elevated cardiovascular disease risk in patients of a secondary prevention setting, their individual risk is heterogeneous. Further risk stratification strategies would be needed to pinpoint extreme high-risk individuals. We have shown previously that plaque burden in coronary arteries assessed by coronary computed tomography angiography was associated with future ASCVD events in patients with FH. In this study, cPS which could be assessed non-invasively, compared with coronary computed tomography angiography, was independently associated with recurrent ASCVD events, while cIMT was not. Although several investigators have examined the predictive value of cIMT and other metrics obtained from carotid ultrasonography, few studies have specifically compared the prognostic value of cIMT and cPS. In the present study, we demonstrated that compared with cIMT, cPS may provide superior risk stratification in patients of a secondary prevention setting.

### Development of Carotid Plaque

Finally, we evaluated the correlation coefficient between age and cPS in each gender (Fig. 4). The regression equations were $Y = 0.245X - 6.63$ ($r = 0.50, p < 0.001$) in male and $Y = 0.189X - 6.09$ ($r = 0.469, p < 0.001$) in female. These results suggest that carotid atherosclerosis had already started to develop, on average, at 27 and 32 years of age in male and female patients with ASCVD, respectively.

### Discussion

The present study compared the clinical utility of 2 different measurements obtained from carotid ultrasonography in patients with ASCVD. This study provides the following important evidence: (1) cPS, rather than cIMT is an independent predictor of MACE (2) cPS is an useful clinical tool for risk stratification (3) On average, carotid atherosclerosis may start to develop at 27 and 32 years of age in male and female patients in a secondary prevention setting, respectively.

Despite the significantly elevated cardiovascular disease risk in patients of a secondary prevention setting, their individual risk is heterogeneous. Further risk stratification strategies would be needed to pinpoint extreme high-risk individuals. We have shown previously that plaque burden in coronary arteries assessed by coronary computed tomography angiography was associated with future ASCVD events in patients with FH. In this study, cPS which could be assessed non-invasively, compared with coronary computed tomography angiography, was independently associated with recurrent ASCVD events, while cIMT was not. Although several investigators have examined the predictive value of cIMT and other metrics obtained from carotid ultrasonography, few studies have specifically compared the prognostic value of cIMT and cPS. In the present study, we demonstrated that compared with cIMT, cPS may provide superior risk stratification in patients of a secondary prevention setting.

#### Table 5. Risk discrimination by carotid intima–media thickness or carotid plaque score beyond traditional risk factors

<table>
<thead>
<tr>
<th>NRI (95% CI)</th>
<th>p value</th>
<th>IDI (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRF Reference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRF + cIMT</td>
<td>0.227 (0.106–0.358)</td>
<td>&lt;0.001</td>
<td>0.0103 (0.0021–0.0365)</td>
</tr>
<tr>
<td>TRF + cPS</td>
<td>0.481 (0.234–0.733)</td>
<td>&lt;0.001</td>
<td>0.021 (0.0051–0.102)</td>
</tr>
</tbody>
</table>

CI, confidence interval; HR, hazard ratio; NRI, net reclassification improvement; IDI, integrated discrimination improvement; TRF, traditional risk factors (age, gender, hypertension, diabetes, smoking, triglyceride, LDL cholesterol, and HDL cholesterol).

#### Fig. 4. Plots of correlation between age (X) and carotid plaque score (Y) in male (A) and female (B) patients with ASCVD

The regression equations were $Y = 0.245X - 6.63$ ($r = 0.50, p < 0.001$) in male and $Y = 0.189X - 6.09$ ($r = 0.469, p < 0.001$) in female.
Carotid Plaque Burden and Recurrence ASCVD

power of cPS especially among the patients with secondary prevention setting. Additionally, cPS could also reflect lower risk situation because of the powerful negative predictive value. Those factors appear to collectively contribute to better risk discriminatory power of cPS, compared with cIMT. Moreover, cPS has been shown as a useful marker for good predictor of cardiovascular mortality even in the very old population. Accordingly, we suggest to assess cPS, rather than cIMT for the risk stratification and as a surrogate marker for the progression of atherosclerosis in patients of a secondary prevention settings, as suggested in the patients with FH.

Based on regression lines from age and cPS among FH patients, we previously reported that carotid atherosclerosis may start to develop at 17 and 26 years of age in male and female FH patients, respectively. In this study, we performed the same analyses, and found that carotid atherosclerosis starts to develop at 27 and 32 years of age in male and female patients of a secondary prevention settings, respectively. These results suggest that carotid atherosclerosis might have already started to develop, at those early ages in particular high-risk population. Therefore, initiating lipid-lowering therapy should be considered before such ages in high-risk population.

The present study had several limitations. First, this was a retrospective study with a small sample size. In addition, we could not include all patients who underwent carotid ultrasonography in the study due to the lack of data. Second, we did not account for medication information, which could affect cIMT and cPS. Third, our assumption of the development of carotid atherosclerosis in such patients is based on a linear model, which may not be applicable to those individuals. Further prospective studies accounting for those limitations are needed to validate our results.

Acknowledgements and Notice of Grant Support

We express special thanks to Ms. Kazuko Honda, Ms. Takako Terakami, Mr. Yoshiyasu Miyajima, and Mr. Sachio Yamamoto (staff of Kanazawa University) for their technical assistance in this study.

Conflicts of Interest

None.

References


4) Hodis HN, Mack WJ, Barth J. Carotid intima-media thickness as a surrogate end point for coronary artery disease. Circulation, 1996; 94: 2311-2312
In total, 2,132 consecutive patients who had any histories of ASCVD events and underwent carotid ultrasonography between January 2006 and December 2015 were retrospectively analyzed. Ninety seven patients lacking data (5%) were excluded.

Supplemental Fig. 2. Bland-Altman plot of cIMT
X-axis represents mean of the difference. Y-axis represents difference. (A) Intraobserver. (B) Interobserver.

Supplemental Fig. 3. Bland-Altman plot of cPS
X-axis represents mean of the difference. Y-axis represents difference. (A) Intraobserver. (B) Interobserver.